1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

 
• By Joseph Haas

New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.

Antibiotic resistant bacteria closeup biofilm

A new international report on encouraging R&D for novel antibiotics says that while governments are contributing an estimated $550m annually toward these efforts, an even higher amount of funding is needed. DRIVE-AB's Revitalizing The Antibiotic Pipeline report recommends both "push" incentives like R&D funding and "pull" incentives such as market-entry rewards to companies that bring novel antibiotics to market as ways to address the rising global issue of drug-resistant microbial infections.

Overall, the report – developed over three years by a task force commissioned by the EU's Innovative Medicines Initiative –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.